NYSE$INSP
Inspire Medical Systems Inc. · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Inspire Medical Systems reported a strong Q4 2023 with revenue growth and net income.
Inspire Medical Systems announced a 40% increase in revenue for the fourth quarter of 2023, reaching $192.5 million. The company reported a net income of $14.8 million, or $0.49 per diluted share, and expanded its U.S. presence by adding 78 new medical centers and 13 new sales territories. They reaffirm full year 2024 revenue to be in the range of $775 million to $785 million.
- Revenue increased by 40% year-over-year to $192.5 million.
- Net income was $14.8 million, with diluted net income per share of $0.49.
- 78 new U.S. centers and 13 new U.S. sales territories were added.
- Reaffirms full year 2024 revenue to be in the range of $775 million to $785 million.
Headline financials
Revenue & EPS history
Inspire · Revenue · Quarterly
$193M
Forward guidance
Inspire is maintaining its full year 2024 revenue guidance of between $775 million to $785 million, which represents growth of 24% to 26% over full year 2023 revenue of $624.8 million. Gross margin for the full year is anticipated to be in the range of 83% to 85%.
Tailwinds
- Full year 2024 revenue guidance of between $775 million to $785 million.
- Revenue growth of 24% to 26% over full year 2023.
- Gross margin for the full year is anticipated to be in the range of 83% to 85%.
- Activate 52 to 56 new U.S. medical centers implanting Inspire therapy during each quarter of 2024.
- Add 12 to 14 new U.S. sales territories during each quarter of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+2.4%
Avg return
Earnings day
+0.8%
Avg return
5 days after
+3.3%
Avg return
30 days after
69%
22 / 32 earnings
Positive
+34.4%
Q3 2020
Best reaction
-34.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -12.2% | -19.2% | -23.1% | |
| Q4 2025 | -12.5% | -11.5% | -14.1% | |
| Q3 2025 | +15.6% | +11.0% | +90.0% | |
| Q1 2025 | +1.6% | -4.7% | -14.4% | |
| Q4 2024 | +1.7% | +2.6% | -12.2% | |
| Q3 2024 | +4.3% | +3.1% | +3.3% | |
| Q2 2024 | +29.5% | +32.8% | +35.6% | |
| Q1 2024 | -34.9% | -33.1% | -37.7% | |
| Q4 2023 | -6.5% | -9.8% | -4.8% | |
| Q3 2023 | -20.9% | -23.5% | -2.1% | |
| Q2 2023 | -3.5% | -3.7% | -21.2% | |
| Q1 2023 | +5.0% | +5.8% | +15.3% | |
| Q4 2022 | +9.7% | +7.9% | -0.4% | |
| Q3 2022 | +6.0% | +6.4% | +22.9% | |
| Q2 2022 | +4.4% | +4.0% | -11.0% | |
| Q1 2022 | -4.5% | -19.8% | -14.4% | |
| Q4 2021 | +5.4% | +0.6% | -1.4% | |
| Q3 2021 | +1.3% | +4.1% | -16.0% | |
| Q2 2021 | +12.9% | +14.4% | +26.1% | |
| Q1 2021 | -16.0% | -17.4% | -29.6% | |
| Q4 2020 | +3.4% | +4.1% | -11.4% | |
| Q3 2020 | +34.4% | +40.7% | +60.3% | |
| Q2 2020 | +7.4% | +3.5% | +17.9% | |
| Q1 2020 | +3.7% | +6.2% | +26.1% | |
| Q4 2019 | +6.4% | +7.7% | -27.2% | |
| Q3 2019 | +4.3% | +4.8% | +21.7% | |
| Q2 2019 | +4.5% | +1.9% | +7.3% | |
| Q1 2019 | -2.5% | -5.7% | -0.6% | |
| Q4 2018 | +5.4% | +5.0% | -4.5% | |
| Q3 2018 | +15.4% | +1.8% | -9.9% | |
| Q2 2018 | -1.8% | -0.1% | +15.6% | |
| Q1 2018 | +10.0% | +6.4% | +20.5% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro